This article was originally published in The Gray Sheet
Patent infringement suit filed in New Jersey federal court alleges that Cytogen's ProstaScint prostate cancer diagnositc imaging agent, co-marketed by Bard, infringes patent 4,460,559 covering antibody-targeted agents for diagnosis and treatment of cancer
You may also be interested in...
Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.